PriceTargets.com logo

Elanco Animal Health - ELAN Stock Price Target and Predictions

  • Consensus Rating: Moderate Buy
  • Consensus Price Target: $27.67
  • Forecasted Upside: 13.06%
  • Number of Analysts: 12
  • Breakdown:
  • 1 Sell Ratings
  • 2 Hold Ratings
  • 8 Buy Ratings
  • 1 Strong Buy Ratings
$24.47 As of 03/4/2026 04:59 PM ET
▼ -0.41 (-1.65%)

This chart shows the closing price for ELAN by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Elanco Animal Health Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for ELAN and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for ELAN

Analyst Price Target is $27.67
▲ +13.06% Upside Potential
This price target is based on 12 analysts offering 12 month price targets for Elanco Animal Health in the last 3 months. The average price target is $27.67, with a high forecast of $30.00 and a low forecast of $23.00. The average price target represents a 13.06% upside from the last price of $24.47.

This chart shows the closing price for ELAN for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Moderate Buy

The current consensus among 12 polled investment analysts is to moderate buy stock in Elanco Animal Health. This rating has held steady since February 2025, when it changed from a Hold consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 5 buy ratings
  • 1 hold ratings
  • 1 sell ratings
Ratings as of
9/11/2024
  • 0 strong buy ratings
  • 4 buy ratings
  • 3 hold ratings
  • 1 sell ratings
Ratings as of
12/10/2024
  • 0 strong buy ratings
  • 3 buy ratings
  • 3 hold ratings
  • 0 sell ratings
Ratings as of
3/10/2025
  • 0 strong buy ratings
  • 3 buy ratings
  • 3 hold ratings
  • 0 sell ratings
Ratings as of
6/8/2025
  • 0 strong buy ratings
  • 5 buy ratings
  • 3 hold ratings
  • 0 sell ratings
Ratings as of
9/6/2025
  • 0 strong buy ratings
  • 8 buy ratings
  • 3 hold ratings
  • 1 sell ratings
Ratings as of
12/5/2025
  • 1 strong buy ratings
  • 8 buy ratings
  • 2 hold ratings
  • 1 sell ratings
Ratings as of
2/3/2026
  • 1 strong buy ratings
  • 8 buy ratings
  • 2 hold ratings
  • 1 sell ratings
Ratings as of
3/5/2026

Latest Recommendations

  • 1 strong buy ratings
  • 8 buy ratings
  • 2 hold ratings
  • 1 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
2/25/2026Morgan StanleyBoost TargetEqual Weight ➝ Equal Weight$22.00 ➝ $24.00
2/25/2026KeyCorpBoost TargetOverweight ➝ Overweight$27.00 ➝ $29.00
2/24/2026Leerink PartnersBoost TargetOutperform ➝ Outperform$26.00 ➝ $30.00
2/19/2026JPMorgan Chase & Co.Boost TargetOverweight ➝ Overweight$24.00 ➝ $28.00
1/29/2026UBS GroupBoost TargetBuy ➝ Buy$27.00 ➝ $30.00
1/22/2026Piper SandlerUpgradeNeutral ➝ Overweight$24.00 ➝ $30.00
12/29/2025Weiss RatingsReiterated RatingSell (D+) ➝ Sell (D+)
12/22/2025Weiss RatingsReiterated RatingSell (D+) ➝ Sell (D+)
12/18/2025Morgan StanleyBoost TargetEqual Weight ➝ Equal Weight$18.00 ➝ $22.00
12/15/2025Weiss RatingsReiterated RatingSell (D+) ➝ Sell (D+)
12/10/2025KeyCorpReiterated RatingOverweight ➝ Overweight
12/9/2025BarclaysInitiated CoverageOverweight$30.00
12/8/2025Weiss RatingsReiterated RatingSell (D+) ➝ Sell (D+)
12/8/2025BarclaysUpgradeStrong-Buy
12/1/2025Weiss RatingsReiterated RatingSell (D+) ➝ Sell (D+)
11/25/2025Weiss RatingsReiterated RatingSell (D+) ➝ Sell (D+)
11/21/2025KeyCorpInitiated CoverageOverweight$27.00
11/20/2025KeyCorpUpgradeStrong-Buy
11/19/2025Weiss RatingsReiterated RatingSell (D+) ➝ Sell (D+)
11/19/2025ArgusUpgradeHold ➝ Buy$25.00
11/13/2025Weiss RatingsReiterated RatingSell (D+) ➝ Sell (D+)
11/7/2025Weiss RatingsDowngradeHold (C-) ➝ Sell (D+)
11/6/2025Zacks ResearchDowngradeStrong-Buy ➝ Hold
11/6/2025UBS GroupBoost TargetBuy ➝ Buy$25.00 ➝ $27.00
10/20/2025UBS GroupBoost TargetBuy ➝ Buy$19.00 ➝ $25.00
10/8/2025Weiss RatingsReiterated RatingHold (C-) ➝ Hold (C-)
10/7/2025JPMorgan Chase & Co.UpgradeNeutral ➝ Overweight$18.00 ➝ $24.00
10/3/2025Zacks ResearchUpgradeHold ➝ Strong-Buy
9/27/2025Weiss RatingsReiterated RatingHold (C-) ➝ Hold (C-)
9/24/2025Stifel NicolausBoost TargetBuy ➝ Buy$18.00 ➝ $23.00
8/20/2025Zacks ResearchDowngradeStrong-Buy ➝ Hold
8/11/2025Piper SandlerBoost TargetNeutral ➝ Neutral$12.00 ➝ $18.00
8/8/2025UBS GroupBoost TargetBuy ➝ Buy$18.00 ➝ $19.00
7/23/2025UBS GroupBoost TargetBuy ➝ Buy$17.00 ➝ $18.00
7/17/2025Leerink PartnersUpgradeMarket Perform ➝ Outperform$18.00
7/2/2025Stifel NicolausBoost TargetBuy ➝ Buy$16.00 ➝ $17.00
6/26/2025William BlairUpgradeMarket Perform ➝ Outperform
5/19/2025Stifel NicolausBoost TargetBuy ➝ Buy$15.00 ➝ $16.00
5/8/2025Stifel NicolausBoost TargetBuy ➝ Buy$13.00 ➝ $15.00
4/14/2025Stifel NicolausLower TargetBuy ➝ Buy$15.00 ➝ $13.00
3/6/2025Piper SandlerLower TargetNeutral ➝ Neutral$16.00 ➝ $12.00
2/26/2025UBS GroupLower TargetBuy ➝ Buy$18.00 ➝ $17.00
2/26/2025Morgan StanleyLower TargetEqual Weight ➝ Equal Weight$14.00 ➝ $13.00
2/26/2025BarclaysLower TargetOverweight ➝ Overweight$20.00 ➝ $19.00
2/21/2025Stifel NicolausLower TargetBuy ➝ Buy$18.00 ➝ $16.00
1/29/2025Morgan StanleyLower TargetEqual Weight ➝ Equal Weight$15.00 ➝ $14.00
1/7/2025Stifel NicolausLower TargetBuy ➝ Buy$20.00 ➝ $18.00
12/9/2024UBS GroupInitiated CoverageBuy$18.00
12/2/2024Leerink PartnersUpgradeHold
12/2/2024Leerink PartnersInitiated CoverageMarket Perform$14.00
11/8/2024BarclaysBoost TargetOverweight ➝ Overweight$19.00 ➝ $20.00
10/28/2024BarclaysLower TargetOverweight ➝ Overweight$22.00 ➝ $19.00
9/23/2024BarclaysBoost TargetOverweight ➝ Overweight$21.00 ➝ $22.00
9/19/2024Stifel NicolausReiterated RatingBuy ➝ Buy$20.00 ➝ $20.00
9/19/2024Morgan StanleyDowngradeOverweight ➝ Equal Weight$17.00 ➝ $15.00
7/1/2024Piper SandlerLower TargetNeutral ➝ Neutral$19.00 ➝ $16.00
6/28/2024BarclaysLower TargetOverweight ➝ Overweight$23.00 ➝ $21.00
5/13/2024Piper SandlerReiterated RatingNeutral ➝ Neutral$18.00 ➝ $19.00
5/9/2024BarclaysBoost TargetOverweight ➝ Overweight$19.00 ➝ $23.00
2/27/2024The Goldman Sachs GroupBoost TargetSell ➝ Sell$12.50 ➝ $14.00
2/27/2024Morgan StanleyBoost TargetOverweight ➝ Overweight$16.00 ➝ $17.00
2/27/2024BarclaysBoost TargetOverweight ➝ Overweight$18.00 ➝ $19.00
1/17/2024The Goldman Sachs GroupBoost TargetSell ➝ Sell$10.00 ➝ $12.50
1/5/2024Stifel NicolausUpgradeHold ➝ Buy$13.00 ➝ $20.00
12/19/2023Jefferies Financial GroupInitiated CoverageBuy$17.00
12/15/2023Morgan StanleyUpgradeEqual Weight ➝ Overweight$16.00
12/7/2023Stifel NicolausBoost TargetHold ➝ Hold$12.00 ➝ $13.00
12/7/2023BNP Paribas ExaneInitiated CoverageOutperform$18.00
11/13/2023Piper SandlerBoost TargetNeutral ➝ Neutral$11.00 ➝ $12.00
11/8/2023Morgan StanleyLower TargetEqual Weight ➝ Equal Weight$17.00 ➝ $16.00
10/30/2023Stifel NicolausLower TargetHold ➝ Hold$13.00 ➝ $12.00
10/5/2023Piper SandlerLower Target$13.00 ➝ $11.00
8/14/2023Piper SandlerBoost TargetNeutral ➝ Neutral$9.00 ➝ $13.00
8/8/2023The Goldman Sachs GroupBoost TargetSell ➝ Sell$8.50 ➝ $9.50
4/20/2023BarclaysUpgradeEqual Weight ➝ Overweight$14.00
3/2/2023Piper SandlerLower Target$15.00 ➝ $12.00
2/22/2023BarclaysLower TargetEqual Weight$18.00 ➝ $14.00
1/30/2023Morgan StanleyLower TargetEqual Weight$20.00 ➝ $19.00
11/15/2022Morgan StanleyLower TargetEqual Weight$21.00 ➝ $20.00
11/14/2022Piper SandlerLower TargetNeutral$21.00 ➝ $15.00
11/9/2022The Goldman Sachs GroupLower TargetSell$19.00 ➝ $12.00
11/8/2022William BlairReiterated RatingMarket Perform
10/17/2022JPMorgan Chase & Co.Lower TargetNeutral$24.00 ➝ $20.00
10/7/2022Morgan StanleyLower TargetEqual Weight$22.00 ➝ $21.00
9/12/2022BarclaysLower TargetEqual Weight$32.00 ➝ $18.00
8/18/2022Morgan StanleyDowngradeOverweight ➝ Equal Weight$37.00 ➝ $22.00
8/16/2022Piper SandlerLower TargetNeutral$22.00 ➝ $21.00
8/16/2022JPMorgan Chase & Co.DowngradeOverweight ➝ Neutral$28.00 ➝ $24.00
7/21/2022The Goldman Sachs GroupDowngradeBuy ➝ Sell$32.00 ➝ $19.00
7/11/2022Piper SandlerInitiated CoverageNeutral$22.00
6/24/2022Stifel NicolausLower TargetHold$30.00 ➝ $22.00
5/19/2022The Goldman Sachs GroupLower TargetBuy$37.00 ➝ $32.00
5/17/2022Morgan StanleyLower TargetOverweight$37.00
2/28/2022BarclaysBoost TargetEqual Weight$30.00 ➝ $32.00
12/8/2021BarclaysReiterated RatingNeutral ➝ Hold
11/18/2021Morgan StanleyInitiated CoverageOverweight$40.00
10/28/2021Stifel NicolausDowngradeBuy ➝ Hold$37.00 ➝ $34.00
8/5/2021Credit Suisse GroupInitiated CoverageOutperform$38.00
5/17/2021CitigroupReiterated RatingBuy$39.00 ➝ $42.00
5/11/2021G.ResearchUpgradeHold ➝ Buy
5/11/2021GabelliUpgradeHold ➝ Buy
5/11/2021BarclaysUpgradeUnderweight ➝ Equal Weight$25.00 ➝ $29.00
4/20/2021Stifel NicolausInitiated CoverageBuy$37.00
4/14/2021Stifel NicolausInitiated CoverageBuy$37.00
3/29/2021GabelliReiterated RatingBuy ➝ Hold$32.00
3/22/2021GabelliDowngradeBuy ➝ Hold$32.00
3/22/2021Raymond James FinancialReiterated RatingHold
3/8/2021CitigroupBoost Target$35.00 ➝ $39.00
(Data available from 3/5/2021 forward)

News Sentiment Rating

0.92 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 1 very positive mentions
  • 12 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
8/7/2025
  • 2 very positive mentions
  • 27 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
Mentions as of
9/6/2025
  • 1 very positive mentions
  • 7 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
Mentions as of
10/6/2025
  • 4 very positive mentions
  • 11 positive mentions
  • 2 negative mentions
  • 1 very negative mentions
Mentions as of
11/5/2025
  • 5 very positive mentions
  • 13 positive mentions
  • 4 negative mentions
  • 0 very negative mentions
Mentions as of
12/5/2025
  • 6 very positive mentions
  • 18 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
1/4/2026
  • 2 very positive mentions
  • 16 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
2/3/2026
  • 31 very positive mentions
  • 34 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
3/5/2026

Current Sentiment

  • 31 very positive mentions
  • 34 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

Elanco Animal Health logo
Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands. The company sells its products to third-party distributors; veterinarians; and farm animal producers, including beef and dairy farmers, as well as pork, poultry, and aquaculture operations. Elanco Animal Health Incorporated was founded in 1954 and is headquartered in Greenfield, Indiana.
Read More

Today's Range

Now: $24.47
Low: $24.41
High: $25.17

50 Day Range

MA: $24.40
Low: $22.38
High: $26.82

52 Week Range

Now: $24.47
Low: $8.02
High: $27.72

Volume

4,090,883 shs

Average Volume

4,574,934 shs

Market Capitalization

$12.17 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.83

Frequently Asked Questions

What sell-side analysts currently cover shares of Elanco Animal Health?

The following sell-side analysts have issued research reports on Elanco Animal Health in the last twelve months: Argus, Barclays PLC, JPMorgan Chase & Co., KeyCorp, Leerink Partners, Morgan Stanley, Piper Sandler, Stifel Nicolaus, UBS Group AG, Wall Street Zen, Weiss Ratings, William Blair, and Zacks Research.
View the latest analyst ratings for ELAN.

What is the current price target for Elanco Animal Health?

0 Wall Street analysts have set twelve-month price targets for Elanco Animal Health in the last year. Their average twelve-month price target is $27.67, suggesting a possible upside of 13.1%. UBS Group AG has the highest price target set, predicting ELAN will reach $30.00 in the next twelve months. Stifel Nicolaus has the lowest price target set, forecasting a price of $23.00 for Elanco Animal Health in the next year.
View the latest price targets for ELAN.

What is the current consensus analyst rating for Elanco Animal Health?

Elanco Animal Health currently has 1 sell rating, 2 hold ratings, 8 buy ratings and 1 strong buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Moderate Buy."
View the latest ratings for ELAN.

What other companies compete with Elanco Animal Health?

Other companies that are similar to Elanco Animal Health include argenex, Teva Pharmaceutical Industries, BeOne Medicines, Insmed and BioNTech. Learn More about companies similar to Elanco Animal Health.

How do I contact Elanco Animal Health's investor relations team?

Elanco Animal Health's physical mailing address is 2500 INNOVATION WAY, GREENFIELD IN, 46140. The company's listed phone number is (877) 352-6261 and its investor relations email address is [email protected]. The official website for Elanco Animal Health is www.elanco.com. Learn More about contacing Elanco Animal Health investor relations.